Tempus AI

Headlines · 1

1. Oct 23
   Pathos AI Raises $237M Series E at $3B Valuation

   Pathos AI announced a $237 million Series E financing at a $3 billion post-money valuation, led by Bristol Myers Squibb with participation from several unnamed returning backers. The company develops cancer drugs with its agentic AI platform, Foundry, which it says can access about 200 petabytes of oncology data. Pathos also announced agreements with Bristol Myers Squibb and Tempus AI involving Foundry access and de-identified data on Alzheimer's disease and other neurological conditions. The supplied reports do not independently validate the platform's performance claims or provide independent clinical-outcome data for Foundry-assisted development.

   SiliconANGLE AI · 🔥 0

Experience and discussion from the community

Share my Tempus AI experienceAsk about Tempus AI